Moreover, beta-blocker therapy should be preferred in hypertensive OSA patients in the presence of CAD, arrhythmia, or heart failure, whereas SGLT-2 inhibitors and renal denervation therapy may be considered as an option in patients refractory to standard therapy. This evidence concerns the gene SLC5A2 and Arrhythmia.